Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR | Market Cap | 488.91M -0.6% |
| Revenue (ttm) | 174.66M +3.0% |
| Net Income | -115.19M |
| EPS | -0.68 |
| Shares Out | 189.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,179,430 |
| Average Volume | 1,516,648 |
| Open | 2.580 |
| Previous Close | 2.578 |
| Day's Range | 2.518 - 2.710 |
| 52-Week Range | 2.135 - 5.415 |
| Beta | 1.33 |
| RSI | 46.76 |
| Earnings Date | May 13, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsNews
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid Financial Challenges
Q1 2026 Valneva SE Earnings Call Transcript
Q1 2026 Valneva SE Earnings Call Transcript
Valneva SE Earnings Call Transcript: Q1 2026
Q1 2026 saw lower revenues and a widened net loss, driven by reduced travel vaccine demand and manufacturing costs. Major cost-cutting and restructuring are underway, with a revised sales outlook and continued R&D focus amid Lyme vaccine uncertainty.
Valneva (VALN) Reports Q1 Loss and Adjusts Revenue Guidance
Valneva (VALN) Reports Q1 Loss and Adjusts Revenue Guidance
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Dan...
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, Ma...
Valneva Announces the Successful Completion of an €84 million Reserved Offering
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty...
Valneva downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Valneva (VALN) to Sell from Neutral with a $4.90 price target Following multiple data disappointments, the company’s outlook is “challenging and comes with significant uncerta...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to conta...
Valneva price target lowered to $11 from $13 at Guggenheim
Guggenheim lowered the firm’s price target on Valneva (VALN) to $11 from $13 and keeps a Buy rating on the shares. The firm adjusted estimates as part of a Q1…
Declaration of shares and voting rights of Valneva SE – March 2026
VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot S...
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will t...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to conta...
Jefferies says Valneva stock weakness presents buying opportunity
Jefferies reiterated a Buy rating and $15 price target on Valneva (VALN) after the company reported topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent OspA-based…
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul...
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
Shares in French specialty vaccine developer Valneva ($VALN) plunged over 38% early Monday despite reporting “clinically meaningful efficacy” results from its late-stage Lyme disease trial with Pfizer...
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
Pfizer (PFE) and Valneva (VALN) announced topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: In ...
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
Valneva SE Earnings Call Transcript: Q4 2025
2025 revenues slightly exceeded prior year, driven by proprietary vaccine growth and disciplined cash management, despite reduced third-party sales. Key pipeline programs advanced, with pivotal Lyme vaccine data expected H1 2026 and Shigella phase II data mid-year.